Vizora日本語

OlympusOLYMPUS CORPORATION7733東証プライム精密機器FY ending Mar 2026, consolidated, IFRS

Olympus FY ending Mar 2022 results

About 54% of Olympus's sales come from Endoscopic Solutions, with Therapeutic Solutions and Scientific Solutions making up much of the rest.

Out of every ¥100 of sales, about ¥20 is left as operating profit.

Revenue changed +2.7% from the prior year, operating profit +78.3%.

Revenue and profit pattern

Revenue and profit upProfit grew faster

Revenue +2.7% · profit +78.3%, calculated from disclosed figures.

Operating leverage: 29.22× (profit growth ÷ revenue growth)

What changed from last year

FY ending Mar 2021 → FY ending Mar 2022

Revenue
+2.7%¥730.5B → ¥750.1B
Gross profit
+10.3%¥459.5B → ¥506.7B
Operating income
+78.3%¥82B → ¥146.2B
Net income attributable to owners
+796.0%¥12.9B → ¥115.7B
Operating cash flow
+36.7%¥124.1B → ¥169.7B
Free cash flow
+66.4%¥64.9B → ¥108B

Where the money goes

FY ending Mar 2021 → FY ending Mar 2022

※ Segment revenues include inter-segment sales and are scaled to consolidated revenue

Where ¥100 of sales goes

For every ¥100 Olympus sells, how much goes where, and how much is kept.

FY ending Mar 2022
Cost of sales
¥32
SG&A
¥48
Operating profit
¥20
Net profit kept
¥15

Annual margin trends

Gross margin67.5%
FY ending Mar 2020: 63.9%63.9%FY ending Mar 2021: 62.9%62.9%FY ending Mar 2022: 67.5%67.5%FY17FY18FY19FY20FY21FY22
Operating margin19.5%
FY ending Mar 2020: 12.2%12.2%FY ending Mar 2021: 11.2%11.2%FY ending Mar 2022: 19.5%19.5%FY17FY18FY19FY20FY21FY22
Net margin15.4%
FY ending Mar 2017: 5.8%5.8%FY ending Mar 2018: 7.3%7.3%FY ending Mar 2019: 1.0%1.0%FY ending Mar 2020: 6.8%6.8%FY ending Mar 2021: 1.8%1.8%FY ending Mar 2022: 15.4%15.4%FY17FY18FY19FY20FY21FY22

Aligned fiscal years compare the shares of revenue remaining as gross, core, and net profit. Missing years are left unconnected.

Which businesses earn the money

Revenue by business segment, and the profit each one keeps.

FY ending Mar 2022
  • Endoscopic Solutions¥461.5B
    54%
    Op. margin 28.9%
  • Therapeutic Solutions¥275.6B
    32%
    Op. margin 22.1%
  • Scientific Solutions¥119.1B
    14%
    Op. margin 14.7%

Profit by segment

※ Segment figures include inter-segment sales and do not sum to the company total

Sources

Show source documents (6)

  • EDINET (FSA Japan)

    有価証券報告書－第158期(2025/04/01－2026/03/31)

    ID S100YDN32026-06-18Open

  • EDINET (FSA Japan)

    有価証券報告書－第157期(2024/04/01－2025/03/31)

    ID S100W0092025-06-19Open

  • EDINET (FSA Japan)

    有価証券報告書－第156期(2023/04/01－2024/03/31)

    ID S100TNZ42024-06-20Open

  • EDINET (FSA Japan)

    訂正有価証券報告書－第155期(2022/04/01－2023/03/31)

    ID S100RV9X2023-09-19Open

  • EDINET (FSA Japan)

    有価証券報告書－第154期(令和3年4月1日－令和4年3月31日)

    ID S100OBAY2022-06-21Open

  • EDINET (FSA Japan)

    有価証券報告書－第153期(令和2年4月1日－令和3年3月31日)

    ID S100LL9I2021-06-21Open

Extracted from XBRL: 46 / Derived from other figures: 1

Spotted an error? Report it (corrections keep the original record)

Other periods

Analyze this page with AI

Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.

Open MarkdownShare on XSave image